BioMedReports has a great piece on why SPPI could be the next cancer biotech takeover target. Spectrum Pharmaceuticals (Nasdaq: SPPI) has two upcoming dates with regulators in the coming days and months. Here are 17 good reasons why Bayer might seriously consider acquiring Spectrum Pharmaceuticals (Nasdaq: SPPI) at some point in the future. Listed below are 17 ongoing clinical trials for Zevalin. Each trial is sorted by its corresponding completion date. Data source: FDA.
Market Club has a very interesting take on how SPPI is playing out after the past volume surge. The “Trade Triangles” paint the picture. CLICK HERE and just enter the ticker (SPPI) your name and e-mail address for the FREE No strings Attached Report sent realtime to your in-box.
SPECTRUM PHARMACEUTICALS (NASDAQ:SPPI)
Smart Scan Chart Analysis confirms a triangle indicates the presence of a very strong trend that is being driven by strong forces and insiders.
FREE Trend Analysis for SPPI Here
